SG11201607400VA - Manufacture of recombinant clostridium botulinum neurotoxins - Google Patents

Manufacture of recombinant clostridium botulinum neurotoxins

Info

Publication number
SG11201607400VA
SG11201607400VA SG11201607400VA SG11201607400VA SG11201607400VA SG 11201607400V A SG11201607400V A SG 11201607400VA SG 11201607400V A SG11201607400V A SG 11201607400VA SG 11201607400V A SG11201607400V A SG 11201607400VA SG 11201607400V A SG11201607400V A SG 11201607400VA
Authority
SG
Singapore
Prior art keywords
manufacture
clostridium botulinum
botulinum neurotoxins
recombinant clostridium
recombinant
Prior art date
Application number
SG11201607400VA
Inventor
Shilpa Palan
Sai Man Liu
Gavin Stephen Hackett
Original Assignee
Ipsen Bioinnovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Bioinnovation Ltd filed Critical Ipsen Bioinnovation Ltd
Publication of SG11201607400VA publication Critical patent/SG11201607400VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/06Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
SG11201607400VA 2014-04-29 2015-04-29 Manufacture of recombinant clostridium botulinum neurotoxins SG11201607400VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1407525.3A GB201407525D0 (en) 2014-04-29 2014-04-29 Manufacture of recombinant clostridium botulinum neurotoxins
PCT/GB2015/051250 WO2015166242A1 (en) 2014-04-29 2015-04-29 Manufacture of recombinant clostridium botulinum neurotoxins

Publications (1)

Publication Number Publication Date
SG11201607400VA true SG11201607400VA (en) 2016-11-29

Family

ID=50972048

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607400VA SG11201607400VA (en) 2014-04-29 2015-04-29 Manufacture of recombinant clostridium botulinum neurotoxins

Country Status (18)

Country Link
US (3) US10307468B2 (en)
EP (3) EP4309668A2 (en)
JP (2) JP6656171B2 (en)
KR (2) KR20230152778A (en)
CN (1) CN106414759B (en)
AU (3) AU2015255068B2 (en)
CA (1) CA2941160A1 (en)
DK (1) DK3137621T3 (en)
EA (1) EA201692188A1 (en)
ES (1) ES2749049T3 (en)
GB (1) GB201407525D0 (en)
HU (1) HUE045564T2 (en)
MX (2) MX2016013803A (en)
PL (1) PL3137621T3 (en)
PT (1) PT3137621T (en)
SA (2) SA520412669B1 (en)
SG (1) SG11201607400VA (en)
WO (1) WO2015166242A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
KR102328155B1 (en) * 2009-06-25 2021-11-17 레반스 테라퓨틱스, 아이엔씨. Albumin-free botulinum toxin formulations
US20120196349A1 (en) * 2009-10-21 2012-08-02 Revance Therapeutics, Inc. Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
JP6156954B2 (en) * 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド Method for producing proteolytically processed polypeptide
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
AU2016310521A1 (en) 2015-08-27 2018-03-01 Massachusetts Institute Of Technology Compositions and methods for treatment of pain
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
KR102423739B1 (en) * 2016-05-27 2022-07-21 입센 바이오팜 리미티드 Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
JP7217700B2 (en) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド Stabilized non-protein Clostridial toxin composition
CN111278454A (en) * 2017-10-13 2020-06-12 威斯康星校友研究基金会 Botulinum neurotoxin subtype A6 and methods of pharmacological use thereof
WO2019158745A1 (en) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
KR102447441B1 (en) * 2019-04-15 2022-09-27 (주)제테마 A Purification Method of Botulinum Toxin
KR102516204B1 (en) 2019-04-15 2023-03-30 (주)제테마 A Purification Method of Botulinum Toxin
GB202003813D0 (en) 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines
AU2021238924A1 (en) 2020-03-16 2022-08-25 Ipsen Biopharm Limited Modified botulinum neurotoxin for treating limb spasticity
CN114958887A (en) * 2021-02-26 2022-08-30 重庆誉颜制药有限公司 Preparation method of modified toxin polypeptide
AU2022348206A1 (en) 2021-09-16 2024-03-28 Ipsen Biopharm Limited Modified bont/a for use in the treatment of cervical dystonia
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
WO2023047127A1 (en) 2021-09-23 2023-03-30 Ipsen Biopharm Limited Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2907695A (en) * 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
DE19856897A1 (en) 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutic to suppress snoring noises
EP1180999A4 (en) * 1999-05-12 2005-03-30 Us Army Medical Res And Materi Recombinant vaccine against botulinum neurotoxin
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
BRPI0508299A (en) * 2005-03-03 2007-07-31 Allergan Inc animal free system and process for purifying a botulinum toxin
ES2369558T3 (en) * 2005-09-19 2011-12-01 Allergan, Inc. CLOSTRIDIAL TOXINS AND ACTIVABLE CLOSTRIDIAL TOXINS.
CN101175478A (en) * 2005-10-06 2008-05-07 阿勒根公司 Non-protein stabilized clostridial toxin pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
US20120196349A1 (en) * 2009-10-21 2012-08-02 Revance Therapeutics, Inc. Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
PL2677029T3 (en) * 2011-05-19 2017-10-31 Ipsen Bioinnovation Ltd Methods for the manufacture of proteolytically processed polypeptides
JP6156954B2 (en) * 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド Method for producing proteolytically processed polypeptide

Also Published As

Publication number Publication date
AU2019219761A1 (en) 2019-09-05
EP3137621B1 (en) 2019-07-17
US20230285521A1 (en) 2023-09-14
MX2020010262A (en) 2020-10-28
SA520412669B1 (en) 2022-08-02
EP3591065B1 (en) 2024-01-10
KR20230152778A (en) 2023-11-03
CA2941160A1 (en) 2015-11-05
JP2017514486A (en) 2017-06-08
EP4309668A2 (en) 2024-01-24
MX2016013803A (en) 2017-03-09
KR102593951B1 (en) 2023-10-26
US20190201505A1 (en) 2019-07-04
JP2020090523A (en) 2020-06-11
HUE045564T2 (en) 2019-12-30
AU2019219761B2 (en) 2021-08-05
ES2749049T3 (en) 2020-03-18
JP6994523B2 (en) 2022-02-04
BR112016022025A2 (en) 2017-10-31
AU2015255068A1 (en) 2016-10-20
WO2015166242A1 (en) 2015-11-05
PL3137621T3 (en) 2020-03-31
KR20160147918A (en) 2016-12-23
CN106414759B (en) 2021-05-28
AU2015255068B2 (en) 2019-05-23
AU2021261858A1 (en) 2021-12-02
GB201407525D0 (en) 2014-06-11
US11642399B2 (en) 2023-05-09
JP6656171B2 (en) 2020-03-04
EP3137621A1 (en) 2017-03-08
EP3591065A1 (en) 2020-01-08
US10307468B2 (en) 2019-06-04
PT3137621T (en) 2019-10-29
CN106414759A (en) 2017-02-15
DK3137621T3 (en) 2019-09-30
US20180117128A1 (en) 2018-05-03
EA201692188A1 (en) 2017-03-31
SA516380060B1 (en) 2021-03-07

Similar Documents

Publication Publication Date Title
SG11201607400VA (en) Manufacture of recombinant clostridium botulinum neurotoxins
HK1249119A1 (en) Engineered botulinum neurotoxin
IL263058A (en) Engineered botulinum neurotoxins
IL262575B (en) Chimeric neurotoxins
HK1208359A1 (en) Recombinant clostridium botulinum neurotoxins
GB201621111D0 (en) Neurotoxins
IL252749B (en) Botulinum toxin prefilled container
HK1249147A1 (en) Methods for enhancing the specific uptake of botulinum neurotoxins into cells
IL250494A0 (en) Stabilized thrombin
IL264109A (en) Production of activated clostridial neurotoxins
HK1255343A1 (en) Recombinant serine proteases
GB201509232D0 (en) Clostridium difficile toxins
GB201405581D0 (en) Recombinant microorganism for improved production of fine chemicals
GB201405579D0 (en) Recombinant microorganism for improved production of fine chemicals
GB201405587D0 (en) Recombinant microorganism for improved production of fine chemicals
GB201405583D0 (en) Recombinant microorganism for improved production of fine chemicals